SPECGX LLC FDA Approval ANDA 040405

ANDA 040405

SPECGX LLC

FDA Drug Application

Application #040405

Documents

Letter2000-09-08

Application Sponsors

ANDA 040405SPECGX LLC

Marketing Status

Prescription001

Application Products

001TABLET;ORAL325MG;7.5MG0ANEXSIA 7.5/325ACETAMINOPHEN; HYDROCODONE BITARTRATE

FDA Submissions

ORIG1AP2000-09-08
LABELING; LabelingSUPPL2AP2001-01-26
LABELING; LabelingSUPPL3AP2001-11-30
MANUF (CMC); Manufacturing (CMC)SUPPL4AP2002-08-08
LABELING; LabelingSUPPL5AP2002-08-26
LABELING; LabelingSUPPL6AP2002-11-13
LABELING; LabelingSUPPL7AP2003-10-10
LABELING; LabelingSUPPL13AP2006-03-27
LABELING; LabelingSUPPL16AP2010-09-15
LABELING; LabelingSUPPL17AP2011-06-24
LABELING; LabelingSUPPL20AP2013-10-25STANDARD
LABELING; LabelingSUPPL23AP2016-12-16STANDARD
LABELING; LabelingSUPPL24AP2016-12-16STANDARD
REMS; REMSSUPPL27AP2018-09-18
LABELING; LabelingSUPPL28AP2018-09-20STANDARD
LABELING; LabelingSUPPL30AP2019-10-11STANDARD
LABELING; LabelingSUPPL34AP2021-03-04STANDARD

Submissions Property Types

SUPPL1Null0
SUPPL2Null1
SUPPL4Null0
SUPPL17Null7
SUPPL20Null7
SUPPL23Null7
SUPPL24Null7
SUPPL27Null15
SUPPL28Null15
SUPPL30Null15
SUPPL34Null7

TE Codes

001PrescriptionAA

CDER Filings

SPECGX LLC
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 40405
            [companyName] => SPECGX LLC
            [docInserts] => ["",""]
            [products] => [{"drugName":"ANEXSIA 7.5\/325","activeIngredients":"ACETAMINOPHEN; HYDROCODONE BITARTRATE","strength":"325MG;7.5MG","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"ANEXSIA 7.5\/325","submission":"ACETAMINOPHEN; HYDROCODONE BITARTRATE","actionType":"325MG;7.5MG","submissionClassification":"TABLET;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">No"}]
            [supplements] => 
            [actionDate] => 1969-12-31
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.